Homocysteine induces vascular endothelial growth factor expression in differentiated THP-1 macrophages

Biochimica et Biophysica Acta - General Subjects

Volumn 1623, Issue 1, 2003, Pages 41-46

  Maeda, Makiko ^a   Yamamoto, Isamu ^a   Fujio, Yasushi ^a   Azuma, Junichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Homocysteine; Macrophage; mRNA; THP 1; Vascular endothelial growth factor

Indexed keywords

BETA ACTIN; CYSTEINE; HOMOCYSTEINE; MESSENGER RNA; METHIONINE; SULFUR DERIVATIVE; VASCULOTROPIN;

ARTICLE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; MACROPHAGE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; UPREGULATION;

EID: 0042733751     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4165(03)00161-2     Document Type: Article

References (36)

1. Mudd S.H., Finkelstein J.D., Irreverre F., Laster L. Homocystinuria: an enzymatic effect. Science. 143:1964;1443-1445.
2. Ress M.M., Rodgers G.M. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb. Res. 71:1993;337-359.
3. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 56:1969;111-128.
4. Malinow M.R. Homocyst(e)ine and arterial occlusive diseases. J. Intern. Med. 236:1994;603-617.
5. Durand P., Lussier-Cacan S., Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J. 11:1997;1157-1168.
6. Duell P.B., Malinow M.R. Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease. Curr. Opin. Lipidol. 8:1997;28-34.
7. Harker L.A., Slichter S.J., Scott C.R., Ross R. Homocysteinemia vascular injury and arterial thrombosis. N. Engl. J. Med. 291:1974;537-543.
8. Tsai J., Perrella M.A., Yoshizumi M., Hsieh C., Harber E., Shlegel R., Lee M. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc. Natl. Acad. Sci. 91:1994;6369-6373.
9. Al-Obaidi M.K., Philippou H., Stubbs P.J., Adami A., Amersey R., Noble M.M., Lane D.A. Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndrome. Circulation. 4:2000;372.
10. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
11. Connolly D.T., Heuvelman D.M., Nelson R., Olander J.V., Eppley B.L., Delfino J.J., Siegel N.R., Leimgruber R.M., Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84:1989;1470-1478.
12. Verheul H.M., Jorna A.S., Hoekman K., Broxterman H.J., Gebbink M.F., Pinedo H.M. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood. 96:2000;4216-4221.
13. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 87:1996;3336-3343.
14. Clauss M., Gerlach M., Gerlach H., Brett J., Wang F., Familletti P.C., Pan Y.C., Olander J.V., Connolly D.T., Stern D. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med. 172:1990;1535-1545.
15. Inoue M., Itoh H., Ueda M., Nakao K. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions - possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 98:1998;2108-2116.
16. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med. 7:2001;425-429.
17. Demuth K., Drunat S., Girerd X., Moatti N., Paul J.L., Safar M., Boutouyrie P. Homocysteine is the only plasma thiol associated with carotid artery remodeling. Atherosclerosis. 165:2002;167-174.
18. Gown A.M., Tsukada T., Ross R. Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am. J. Pathol. 125:1986;191-207.
19. Tsuchiya S., Yamabe M., Yoshihiko Y., Kobayashi Y., Konno T., Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer. 26:1980;171-176.
20. Tsuchiya S., Kobayashi Y., Goto Y., Okumura H., Nakae S., Konno T., Tada K. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res. 42:1982;1530-1536.
21. Ueda A., Ishigatsubo Y., Okubo T., Yoshimura T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-κB sites and NF-κB/Rel subunit specificity. J. Biol. Chem. 272:1997;31092-31099.
22. Via D.P., Pons L., Dennison D.K., Franslow A.E., Bernini F. Induction of acetyl-LDL receptor activity by phorbol ester in human monocyte cell line THP-1. J. Lipid Res. 30:1989;1515-1524.
23. Tangirala R.K., Murao K., Quehenberger O. Regulation of expression of the human monocyte chemotactic protein-1 receptor (hCCR2) by cytokines. J. Biol. Chem. 272:1997;8050-8056.
24. Berse B., Brown L.F., Van de Water L., Dvorak H.F., Senger D.R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell. 3:1992;211-220.
25. Ramos M.A., Kuzuya M., Esaka T., Miura S., Satake S., Asai T., Kanda S., Hayashi T., Iguchi A. Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 18:1998;1188-1196.
26. 2 modulation of vascular endothelial growth factor production in murine macrophages. Prostaglandins Leukot. Essent. Fat. Acids. 65:2001;123-131.
27. Wang G., Siow Y.L., O K. Homocysteine induces monocyte chemoattractant protein-1 expression by activating NF-κB in THP-1 macrophages. Am. J. Physiol., Heart Circ. Physiol. 280:2001;H2840-H2847.
28. Hofmann M.A., Lalla E., Lu Y., Gleason M.R., Wolf B.M., Tanji N., Ferran L.J. Jr., Kohl B., Rao V., Kisiel W., Stern D.M., Schmidt A.M. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J. Clin. Invest. 107:2001;675-683.
29. Kiriakidis S., Andreakos E., Monaco C., Foxwell B., Feldmann M., Paleolog E. VEGF expression in human macrophages is NF-κB-dependent: studies using adenoviruses expressing the endogenous NF-κB inhibitor IκBalpha and a kinase-defective form of the IκB kinase 2. J. Cell. Sci. 116:2003;665-674.
30. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N. Engl. J. Med. 338:1998;1042-1050.
31. Kang S.S., Wang P.W.K., Malinow M.R. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Annu. Rev. Nutr. 12:1992;279-298.
32. Ueland P.M., Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J. Lab. Clin. Med. 114:1989;473-501.
33. McCully K.S. Homocysteine and vascular disease. Nat. Med. 2:1996;386-389.
34. Bissonnette R., Treacy E., Rozen R., Boucher B., Cohn J.S., Genest J. Jr. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis. 155:2001;455-462.
35. Ikeda U., Ikeda M., Minota S., Shimada K. Homocysteine increases nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells. Circulations. 99:1999;1230-1235.
36. Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ullmann D., Tishler P.V., Hennekens C.H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 268:1992;877-881.